Title

Analytic sensitivity of the Abbott BinaxNOW[™] lateral flow immunochromatographic assay for the SARS-CoV-2 Omicron variant

Authors

Sanjat Kanjilal^{1,2}, Sujata Chalise^{2,3}, Adnan Shami Shah^{2,3}, Chi-An Cheng^{2,3}, Yasmeen Senussi^{2,3}, Michael Springer⁴, David R. Walt^{2,3}

Affiliations

¹Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Healthcare Institute, Boston, MA

²Department of Pathology, Brigham & Women's Hospital and Harvard Medical School, Boston, MA

³Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA ⁴Department of Systems Biology, Harvard Medical School, Boston, MA

Corresponding author

Sanjat Kanjilal, MD MPH Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Healthcare Institute Boston, MA 02215 Email: <u>skanjilal@bwh.harvard.edu</u>

Word count

2136

Abstract

The emergence of the SARS-CoV-2 Omicron variant has motivated a re-evaluation of the test characteristics for lateral flow immunochromatographic assays (LFIAs), commonly referred to as rapid antigen tests. To address this need, we evaluated the analytic sensitivity of one of the most widely used LFIAs in the US market, the Abbott BinaxNOW[™] COVID-19 Ag At-Home Card using 32 samples of Omicron and 30 samples of the Delta variant. Samples were chosen to intentionally over-represent the range of viral loads where differences are most likely to appear. We found no changes in the analytic sensitivity of the BinaxNOW[™] assay by variant even after controlling for variation in cycle threshold values in the two populations. Similar to prior studies, the sensitivity of the assay is highly dependent on the amount of virus present in the sample. While the analytic sensitivity of the BinaxNOW[™] LFIA remains intact versus the Omicron variant, its clinical sensitivity is influenced by the interaction between viral replication, the dynamics of tissue tropism and the timing of sampling. Further research is necessary to optimally adapt current testing strategies to robustly detect early infection by the Omicron variant to prevent transmission.

1 Introduction

2 The identification of infection by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), aids the individual by prompting 3 timely initiation of treatment and aids the public by allowing for separation of contagious hosts 4 from susceptible secondary contacts. Lateral flow immunochromatographic (LFIAs) assays, 5 commonly referred to as rapid antigen tests, are an important element of pandemic containment 6 as they provide results within 15 minutes and can be performed by the public without supervision. 7 However, a drawback is their lower analytic sensitivity relative to nucleic acid amplification based 8 assays like the reverse transcriptase polymerase chain reaction (RT-PCR). In practice, the impact 9 of this drop in sensitivity is limited to the brief window during which a person is efficiently 10 transmitting live virus but still has viral loads below the limit of detection (LoD) of the LFIA. In prior 11 waves of COVID-19, this time period is estimated to be days 1 to 2 post-infection¹. Tests taken 12 during that time window have a risk of being falsely negative and can lead individuals to transmit 13 14 the virus to others unbeknownst to them.

15

16 The COVID-19 pandemic has spread in a series of waves due to the successive emergence of 17 variants of concern (VOCs) that contain sets of mutations that confer selective advantages over 18 prior lineages due to improved transmissibility, immune escape, and more efficient viral 19 replication. These mutations are concentrated in the spike protein as it is the target of greatest 20 immune pressure, but VOCs also contain single nucleotide polymorphisms in the nucleocapsid (N) protein, which encapsidates the viral RNA. The recently emerged Omicron variant has a 21 mutation (P13L) and a deletion (d31-33) in the N-terminal domain, and two changes in the central 22 23 linker domain (R203K and G204R²) that have not yet been fully characterized.

24

25 The N protein is the target analyte for the majority of LFIAs currently approved for emergency use by the US Food and Drug Administration (FDA). These assays typically use monoclonal 26 antibodies coupled to nanoparticles to bind epitopes present on the SARS-CoV-2 N protein, which 27 28 are then carried by capillary action to a detection line where the complex is bound by a second monoclonal antibody which binds elsewhere to the SARS-CoV-2 N protein. The resulting 29 concentrated nanoparticle can be visualized by eye. The regions of the protein to which antibodies 30 31 are raised are derived either from the wild type strain or early VOCs such as the Alpha variant. The precise epitopes targeted by the commercially-available LFIAs are proprietary, therefore 32 33 independent evaluation is necessary to evaluate whether changes to nucleocapsid protein in the 34 Omicron variant affect the analytic sensitivity of the test. Given the critical role that LFIAs play in

- early case detection and return to work assessments, quantifying changes in test performance is
- of high value to the scientific community, policy makers and the public.
- 37
- In this study we report the analytic sensitivity of the widely used Abbott BinaxNOW™ COVID-19
- Ag Card against the Omicron variant, using the Delta variant as a reference. Our primary
- 40 hypothesis is that the analytic sensitivity of the Abbott BinaxNOW™ LFIA will be unaffected by
- 41 the nucleocapsid mutations specific to the Omicron variant.

42 Methods

43 We utilized 32 specimens positive for the Omicron variant and 30 positive for the Delta variant, collected between December 16th 2021 and December 18th 2021 as part of Harvard University's 44 asymptomatic SARS-CoV-2 student and staff screening program. During the time period of 45 collection, >98% of the community was fully vaccinated. All samples were obtained from the 46 anterior nares of individuals using a RHINOstic nasal swab (Rhinostics, Boston, MA) and initially 47 placed into a sterile dry tube. Upon reaching the central testing laboratory, samples were eluted 48 into 300µl of phosphate buffered saline and inactivated at 65°C for 30 minutes. All samples were 49 received by the laboratory and eluted within 24 hours. Real-time RT-PCR was performed using 50 the Quaeris SARS-CoV-2 assay with fluorescence and cycle thresholds (Cts) for the N and RdRP 51 genes determined by the Applied Biosystems RT-PCR instrument running the QuantStudio 7 52 Design and Analysis Desktop Software, version 1.7. Details of the protocol can be found in the 53 FDA Emergency Use Authorization summary for the Harvard University Clinical Laboratory 54 (HUCL) assay³. The LoD of the assay is 2.5 RNA copies / µl. 55

56

Samples were genotyped using a multiplex PCR assay with primers specific to both variants. Based on the expected limit of detection (LoD) for the BinaxNOWTM LFIA⁴, we weighted our samples to over-represent those with Ct values below 30 as this is where differences in analytic sensitivity would most likely appear. The final analysis for the Delta variant samples consisted of 22 samples with Ct < 30 and 8 samples with Ct ≥ 30. The final analysis for the Omicron variant samples consisted of 24 samples with Ct < 30 and 8 samples with Ct ≥ 30.

63

After RT-PCR analysis, the specimens selected for this analysis were frozen once at -20°C. For 64 LFIA testing, 50µl of each sample was placed in a 1.5ml microcentrifuge tube into which the kit-65 supplied swab was placed and rotated for 15 seconds. This volume was chosen based on a prior 66 study that determined 50µl to be the optimal volume for balancing the ratio of analyte to kit-67 supplied running buffer for *in vitro* testing of samples with the BinaxNOW^{™4}. Based on our 68 observations, we noted that on average 5µl of sample remained in the tube after swab rotation. 69 All subsequent steps for sample evaluation were per the assay's Instructions For Use⁵. Briefly, 70 six drops of kit-supplied running buffer were placed into the top hole of the card and swabs were 71 72 inserted into the bottom hole and pushed upwards until the tip was in contact with the buffer. The cards were then sealed and read twice after 15 minutes by two independent readers blinded to 73 74 the identity of the sample. A third reader was used for any discordant reads and a photo was 75 taken of the card after the completion of the incubation period. All samples were run in triplicate.

76

Descriptive statistics were performed using chi-squared tests or Fisher's exact test for categorical variables and 2-sample t-tests for comparing Ct values by variant. Logistic regression was used to estimate the odds ratio of a positive LFIA test given variant type after accounting for Ct value differences. All analyses were performed in R, version 4.1.2. This study was deemed non-human subjects research and approved by the Mass General Brigham Institutional Review Board (protocol 2021P003604).

83 Results

A total of 62 samples were run in triplicate (30 Delta samples and 32 Omicron samples). Only 2 samples differed within technical replicates and there were no differences by reader, therefore all results represent the data obtained from a single replicate and reader 1. Table 1 shows the distribution of Ct values for the samples chosen for this analysis did not differ by variant.

Variant	Sample size	Median Ct value (IQR)	p value	
Delta	30	27 (5.88)	0.94	
Omicron	32	27 (6.02)		

Table 1: Baseline distribution of Ct values by SARS-CoV-2 variant. IQR, interquartile range. 90

The BinaxNOW[™] test was positive in 9 of 22 (41%) Delta samples and in 8 of 24 (33%) Omicron

samples with Ct < 30. It was positive in 1 of 7 (12%) Delta samples and in 0 of 8 (0%) Omicron

samples with $Ct \ge 30$. There were no statistically significant differences between the variants with

- respect to test positivity for either Ct range (Table 2). The complete dataset for this study is
- 95 available by request.

Ct range	Variant	BinaxNOW™ result	N (percent)	p value
<30	Delta	Negative	13 (59%)	0.82
		Positive	9 (41%)	
	Omicron	Negative	16 (67%)	
		Positive	8 (33%)	
≥30	Delta	Negative	7 (88%)	1.00
		Positive	1 (12%)	
	Omicron	Negative	8 (100%)	
		Positive	0 (0%)	

96 Table 2: Distribution of BinaxNOW[™] LFIA results stratified by Ct value ranges and SARS-

⁹⁷ CoV-2 variant.

Figure 1 shows the distribution of positive and negative results by Ct value and variant. The expected LoD for the BinaxNOW[™] is estimated to be 40,000 to 80,000 RNA copies per swab, which is derived from samples obtained prior to the emergence of the Delta variant⁴. This corresponds approximately to a Ct of 25 on the HUCL assay based on previously performed standard curve data normalized to the sample volume taken up by the swab. Two of 10 (20%) Delta variant samples and 5 of 11 (45%) Omicron samples were negative despite having levels of virus above the LoD.





106

107 Figure 1: Distribution of BinaxNOW[™] antigen test results by Ct value and SARS-CoV-2

variant. The y-axis indicates the Ct value of the positive sample. The pink horizontal band
represents the expected LoD range of the BinaxNOW[™], based on work from Perchetti et al⁴ and
standard curve data for the HUCL RT-PCR assay.

111

After adjustment for each sample's Ct value, there was no difference in the odds of test positivity

for the Omicron variant versus the Delta variant (odds ratio 0.41; 95% CI 0.07 - 2.0).

114 Discussion

115 The emergence of the Omicron variant in mid-November 2021 was followed by many anecdotal reports of false negative LFIA tests. In this study, we found no significant difference in the analytic 116 sensitivity of the widely used Abbott BinaxNOW™ COVID-19 Ag Card LFIA for the N protein of 117 the SARS-CoV-2 Omicron variant with respect to the Delta variant. We noted a greater proportion 118 of negative samples containing viral loads above the assay's LoD for Omicron specimens than 119 for Delta specimens, but this finding did not reach statistical significance, possibly due to our 120 study's small sample size. Given that N protein mutations have been shown to impact LFIA 121 performance in the past⁶, these findings provide a degree of reassurance that the assay is 122 performing as expected. 123

124

Our results reinforce the findings of a smaller study that also examined the analytic sensitivity of 125 the BinaxNOW[™] versus Omicron with respect to its ability to detect both variants and in the 126 estimated amount of nucleocapsid protein necessary to visualize a signal⁷. Our findings extend 127 that work by including a larger number of independently collected clinical specimens and widening 128 the range of viral loads in the sample set. Our results are also in agreement with the study by 129 Deerain et al, which utilized serial dilutions of Omicron and Delta samples derived from viral 130 131 cultures⁸. In that study, there was no difference in the analytic sensitivity for the Abbott Panbio[™] 132 COVID-19 Ag Rapid Test Device, which utilizes the same epitopes as the Abbott BinaxNOW™ COVID-19 Ag Card test marketed in the United States. Similarly, our findings agree with a recently 133 published study from Schrom et al evaluating the analytic sensitivity of the BinaxNOW[™] using 134 135 paired RT-PCR anterior nares specimens obtained from a community testing center in San Francisco with a high rate of test positivity⁹. Our study provides complementary information to 136 their findings by quantifying the threshold for detection in RNA copy numbers per swab and by 137 comparing results with Omicron to Delta variant samples, which enables us to determine the 138 degree of performance drift. Finally, our study is in line with announcements from the 139 manufacturer¹⁰ regarding the performance of the LFIA, though the data underlying their press 140 release are not publicly available. 141

142

Independent of whether the analytic sensitivity for the BinaxNOW[™] remains intact, the real-world performance of the test may still substantially differ from its use during prior waves of the COVID-145 pandemic. This is because the clinical sensitivity of an assay is influenced by factors inherent to the virus as well as host factors such as pre-existing immunity. For instance, Abramson et al reported the propensity for the BinaxNOW[™] and the Quidel Quickvue[™] LFIAs to be falsely

negative early in infection despite very high viral loads detected concomitantly from saliva samples¹¹. Antigen detection from nasal swab samples eventually turned positive several days after symptom onset, suggesting that viral replication may initially localize to the oropharynx prior to transitioning to the nasopharynx. A study by Marais et al also found higher viral loads in saliva compared to paired mid-turbinate swabs but did not follow study participants over time to document a transition¹². The BinaxNOW[™] is currently only approved for use with anterior nares swabs in the US⁵.

155

Our results may be affected by the use of heat-inactivated samples that underwent one freeze-156 thaw cycle prior to analysis. However, this is not likely to have had a major impact on assay 157 158 performance, as samples would have undergone denaturation regardless and the period of time 159 they were frozen was short. The consistency of our data with prior studies defining the analytic sensitivity of the BinaxNOW™ as well as the lack of variation within technical replicates and 160 across multiple blinded readers, further suggests that our findings are reproducible. Although our 161 sample modality was not identical to a nares swab, we utilized a volume of media (50 µl) that has 162 been shown to be approximately equal to the volume of mucus expected to be taken up by a 163 164 swab when used *in vivo*⁴.

165

In summary, we found no difference in the analytic sensitivity of the Abbott BinaxNOW™ COVID-166 19 Ag Card for the Omicron variant relative to contemporaneously collected Delta variant 167 samples. If sufficient virus is present in a sample, the assay should be expected to turn positive. 168 169 The clinical (ie 'real-world') sensitivity of the assay is impacted by the viral load in the nares at the 170 time of sampling, which in turn is influenced by variant-specific replication kinetics and host immunity. Increasing data suggests this may be the primary driver for the anecdotal reports of 171 false negative LFIA results soon after symptom onset. Larger studies performing serial sampling 172 from the oropharynx and nasopharynx with quantitative measures of viral loads in symptomatic 173 and asymptomatic people will provide critical data for informing case detection algorithms. 174

175

176 Acknowledgements

177 This study was funded by a grant from the Massachusetts Consortium for Pathogen Readiness.

178

179 Conflicts of interest

180 SK is the editor for the diagnostics section of the Infectious Diseases Society of America COVID-

181 19 Real-time Learning Network. No other authors have any financial conflicts of interest.

References

- 1. Kissler, S. M. et al. Viral dynamics of acute SARS-CoV-2 infection and applications to diagnostic and public health strategies. Plos Biol 19, e3001333 (2021).
- CoVariants.org. https://covariants.org/variants/21K.Omicron (n.d.). Accessed Jan 6 2022.
- Emergency Use Authorization Summary: Quaeris SARS-CoV-2 Assay, Harvard University Clinical Laboratory. <u>https://www.fda.gov/media/149445/download</u>. Accessed Jan 7 2022.
- 4. Perchetti, G. A., Huang, M.-L., Mills, M. G., Jerome, K. R. & Greninger, A. L. Analytical Sensitivity of the Abbott BinaxNOW COVID-19 Ag Card. J Clin Microbiol 59, (2021).
- 5. Abbott BinaxNOW COVID-19 Ag At-Home Card Instructions For Use. https://www.fda.gov/media/144574/download (n.d.).
- 6. Bourassa, L. et al. A SARS-CoV-2 Nucleocapsid Variant that Affects Antigen Test Performance. J Clin Virol 141, 104900 (2021).
- Regan, J. et al. Detection of the omicron variant virus with the Abbott BinaxNow SARS-CoV-2 Rapid Antigen Assay. Medrxiv 2021.12.22.21268219 (2021) doi:10.1101/2021.12.22.21268219.
- 8. Deerain, J. et al. Assessment of the analytical sensitivity of ten lateral flow devices against the SARS-CoV-2 omicron variant. J Clin Microbiol jcm0247921 (2021) doi:10.1128/jcm.02479-21.
- Schrom, J. et al. Direct Comparison of SARS Co-V-2 Nasal RT- PCR and Rapid Antigen Test (BinaxNOWTM) at a Community Testing Site During an Omicron Surge. 2022.01.08.22268954 (2022) doi:10.1101/2022.01.08.22268954.
- 10. An Update on Omicron and Test Effectiveness. <u>https://www.abbott.com/corpnewsroom/diagnostics-testing/an-update-on-omicron-and-test-effectiveness.html</u>. Accessed Jan 8 2022.
- Adamson, B. J., Sikka, R., Wyllie, A. L. & Premsrirut, P. K. Discordant SARS-CoV-2 PCR and Rapid Antigen Test Results When Infectious: A December 2021 Occupational Case Series. (n.d.) doi:10.1101/2022.01.04.22268770.
- 12. Marais, G. et al. Saliva swabs are the preferred sample for Omicron detection. Medrxiv 2021.12.22.21268246 (2021) doi:10.1101/2021.12.22.21268246.